Share Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

PRNewsWire · PINC · November 4, 2026

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: PRNewsWire ↗